{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:50:27Z","timestamp":1772740227196,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.clinthera.2011.10.022","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T03:24:31Z","timestamp":1321413871000},"page":"2029-2037","source":"Crossref","is-referenced-by-count":31,"title":["Comparative Pharmacokinetics and Tolerability of Branded Etanercept (25 mg) and Its Biosimilar (25 mg): A Randomized, Open-Label, Single-Dose, Two-Sequence, Crossover Study in Healthy Korean Male Volunteers"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"kct0000118","registry":"10.18810\/cris"}],"author":[{"given":"Namyi","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SoJeong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JaeWoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.10.022_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","article-title":"Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics","volume":"223","author":"Feldmann","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2011.10.022_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/sarh.2001.23704","article-title":"Uncoupling of inflammatory and destructive mechanisms in arthritis","volume":"30","author":"van den Berg","year":"2001","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2011.10.022_bib3","first-page":"ii11","article-title":"Pathogenesis of bone and cartilage destruction in rheumatoid arthritis","volume":"42","author":"Goldring","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2011.10.022_bib4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/ard.47.9.768","article-title":"Tumour necrosis factor in synovial exudates","volume":"47","author":"Di Giovine","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2011.10.022_bib5","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.10.022_bib6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1476-5381.2010.01099.x","article-title":"Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors","volume":"162","author":"Mewar","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.022_bib8","first-page":"1376","article-title":"This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2011.10.022_bib12","series-title":"Guidance for Industry, Bioanalytical Method Validation","year":"2001"},{"key":"10.1016\/j.clinthera.2011.10.022_bib13","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/01.CIR.81.6.1803","article-title":"Spectral characteristics of heart rate variability before and during postural tilt","volume":"81","author":"Lipsitz","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2011.10.022_bib14","series-title":"Pharmacokinetics in Drug Development","author":"Bonate","year":"2004"},{"key":"10.1016\/j.clinthera.2011.10.022_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1345\/aph.19126","article-title":"The pharmacokinetics of etanercept in healthy volunteers","volume":"34","author":"Korth-Bradley","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2011.10.022_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0091270006286435","article-title":"The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects","volume":"46","author":"Kawai","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.022_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0091270004264164","article-title":"Absence of a pharmacokinetic interaction between etanercept and warfarin","volume":"44","author":"Zhou","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.022_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.022_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0009-9236(02)17635-1","article-title":"Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis","volume":"73","author":"Lee","year":"2003","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T09:26:52Z","timestamp":1543397212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811007119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0149291811007119"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.10.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}